A Phase 1/2 interventional study of ARN-509 (Phase 1) and ARN-509 (Phase 2) in Prostate Cancer, sponsored by Aragon Pharmaceuticals, Inc.. Completed at 15 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by Aragon Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.
Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 23rd largest by enrollment, is the only one that started in 2010, is one of 2 in phase 1/2, and was the 1st registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
Marco Oderda · Sites in Italy
Ages 18–80 · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+ · Men only
Cambridge University Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only
By country, each count listing its studies:
apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 39 · Phase 3 16 · Phase 4 2
First in 2010; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 127 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 81 across the 70 interventional studies. Of the 29 that completed or were terminated, 16 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 70 have an industry lead sponsor. The 10 most frequent:
This study is registered under Aragon Pharmaceuticals, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Aragon Pharmaceuticals, Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 29th largest by enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2010, is one of 4 in phase 1/2, and was the 19th registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
9 of the studies testing apalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT06274047Phase 3M.D. Anderson Cancer CenterPROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. | 2027-06-30 |
| NCT06067269Jonsson Comprehensive Cancer CenterHormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial | 2026-12-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 70 studies testing apalutamide in Prostatic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer. Patients will first be enrolled into Phase 1 of the study to identify a tolerable dose for the Phase 2 portion of the study. In the Phase 2, 3 different cohorts of patients will be enrolled to evaluate the safety and activity of ARN-509.
NON- CRPC
Inclusion Criteria
Exclusion Criteria
METASTATIC CRPC, TREATMENT-NAIVE
Inclusion Criteria
Exclusion Criteria
METASTATIC CRPC, CHEMOTHERAPY-NAIVE, POST-ABIRATERONE
Inclusion Criteria
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily. Once Recommended Phase 2 Dose (RP2D) has been selected, Phase 1 participants being treated at the lower dose levels will be allowed to escalate to the RP2D level at the discretion of the primary investigator.
Drug: ARN-509 (Phase 1)
Participants with non-metastatic, treatment-naive Castration-Resistant Prostate Cancer (CRPC) with rapidly rising Prostate Specific Antigen (PSA) will be enrolled. ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
Drug: ARN-509 (Phase 2)
Participants with treatment-naive metastatic CRPC will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.
Drug: ARN-509 (Phase 2)
Participants with metastatic CRPC that are chemotherapy-naive, but have been previously treated with abiraterone will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.
Drug: ARN-509 (Phase 2)
ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily.
ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
Phase 1 and 2: Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) at Week 12
Percentage of participants with \>=50% decrease in PSA compared to baseline were assessed at Week 12. PSA progression was defined by the protocol-specific Prostate Cancer Working Group 2 (PCWG2) criteria: PSA increase greater than or equal to \[\>=\] 25 percent \[%\] and \>=2 nanogram per milliliter \[ng/mL\] above the nadir confirmed \>=3 weeks later; or \>=25% and \>=2 ng/mL above baseline PSA after 12 weeks.
Time frame: Week 12
Phase 1 and 2: Median Time to PSA Progression
Time to PSA progression was measured as the time interval from the date of the first dose to the date of PSA progression as defined by the PCWG2 criteria. PCWG2 criteria: For participants who achieved \>=50% decrease from the baseline PSA, assessment of time to disease progression was when the PSA increased 25% and at a minimum of 2 ng/mL above the nadir at 3 or more weeks later. For participants without a PSA decrease, the time for progression was calculated at the time when the PSA progression was \>=25% and \>=2 ng/mL after 12 weeks.
Time frame: Up to approximately 7 years
Phase 2: Median Metastasis-Free Survival (MFS)
MFS was defined as the time from the start of treatment until new metastatic lesions were observed on Computed Tomography/ Magnetic Resonance Imaging (CT/MRI) scans or radionuclide bone scans (according to PCWG2 criteria: appearance of \>=2 new lesions, and, for the first reassessment only, a confirmatory scan performed 6 or more weeks later that showed at least 2 or more additional new lesions) or death, whichever occurred first.
Time frame: Up to approximately 7 years
Phase 1 and 2: Progression-free Survival (PFS)
PFS was defined as the time from randomization to the radiographic disease progression or death, whichever occurred first. Radiographic progression defined by at least one of the following: a) Soft tissue progression by modified RECIST confirmed on repeat imaging \>= 6 weeks later; b) Progression by bone scans: 1) first bone scan with \>= 2 new lesions compared to baseline observed \<12 weeks from start date and confirmed on a second bone scan \>=6 weeks later that showed \>=2 additional lesions (a total of \>=4 new lesions compared to baseline); or 2) first bone scan with \>=2 new lesions compared to baseline observed \>=12 weeks from start date and the new lesions verified on the next bone scan \>=6 weeks later (a total of \>=2 new lesions compared to baseline).
Time frame: Up to approximately 7 years
Phase 1 and 2: Objective Response Rate
Objective Response Rate was defined as the percentage of participants with best overall response (OR) of confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.0 (RECIST). Where, CR defined as disappearance of all target lesions. Any pathological lymph nodes must had reduction in short axis to less than 10 millimeter (mm). PR defined as at least 30 percent (%) decrease in sum of the diameters of the target lesions. Confirmed responses were those that persisted on repeat imaging study for at least 4 weeks after initial documentation of response.
Time frame: Up to approximately 7 years
| Milestone | Dose Escalation Cohort (Phase 1) | Cohort 1: Non-metastatic CRPC (Phase 2) | Cohort 2: Treatment-naive Metastatic CRPC (Phase 2) | Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2) |
|---|---|---|---|---|
| Started | 30 | 51 | 25 | 21 |
| Completed | 26 | 32 | 13 | 15 |
| Not completed | 4 | 19 | 12 | 6 |
| Withdrew: Death | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 4 | 6 | 3 |
| Withdrew: Terminated by sponsor | 1 | 0 | 0 | 0 |
| Withdrew: Ongoing | 1 | 9 | 3 | 0 |
| Withdrew: Other | 1 | 5 | 0 | 2 |
Percentage of participants with \>=50% decrease in PSA compared to baseline were assessed at Week 12. PSA progression was defined by the protocol-specific Prostate Cancer Working Group 2 (PCWG2) criteria: PSA increase greater than or equal to \[\>=\] 25 percent \[%\] and \>=2 nanogram per milliliter \[ng/mL\] above the nadir confirmed \>=3 weeks later; or \>=25% and \>=2 ng/mL above baseline PSA after 12 weeks.
| Percentage of Participants | Dose Escalation Cohort (Phase 1) | Cohort 1: Non-metastatic CRPC (Phase 2) | Cohort 2: Treatment-naive Metastatic CRPC (Phase 2) | Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2) |
|---|---|---|---|---|
| Phase 1 and 2: Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) at Week 12 | 47 | 89 | 88 | 22 |
Time to PSA progression was measured as the time interval from the date of the first dose to the date of PSA progression as defined by the PCWG2 criteria. PCWG2 criteria: For participants who achieved \>=50% decrease from the baseline PSA, assessment of time to disease progression was when the PSA increased 25% and at a minimum of 2 ng/mL above the nadir at 3 or more weeks later. For participants without a PSA decrease, the time for progression was calculated at the time when the PSA progression was \>=25% and \>=2 ng/mL after 12 weeks.
| Months | Dose Escalation Cohort (Phase 1) | Cohort 1: Non-metastatic CRPC (Phase 2) | Cohort 2: Treatment-naive Metastatic CRPC (Phase 2) | Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2) |
|---|---|---|---|---|
| Phase 1 and 2: Median Time to PSA Progression | 4.9 (3.9 to 9.5) | 24.0 (16.30 to 35.0) | 16.5 (5.6 to 59.5) | 3.0 (2.7 to 4.7) |
MFS was defined as the time from the start of treatment until new metastatic lesions were observed on Computed Tomography/ Magnetic Resonance Imaging (CT/MRI) scans or radionuclide bone scans (according to PCWG2 criteria: appearance of \>=2 new lesions, and, for the first reassessment only, a confirmatory scan performed 6 or more weeks later that showed at least 2 or more additional new lesions) or death, whichever occurred first.
| Months | Cohort 1: Non-metastatic CRPC (Phase 2) |
|---|---|
| Phase 2: Median Metastasis-Free Survival (MFS) | 21.6 (11.5 to 40.9) |
PFS was defined as the time from randomization to the radiographic disease progression or death, whichever occurred first. Radiographic progression defined by at least one of the following: a) Soft tissue progression by modified RECIST confirmed on repeat imaging \>= 6 weeks later; b) Progression by bone scans: 1) first bone scan with \>= 2 new lesions compared to baseline observed \<12 weeks from start date and confirmed on a second bone scan \>=6 weeks later that showed \>=2 additional lesions (a total of \>=4 new lesions compared to baseline); or 2) first bone scan with \>=2 new lesions compared to baseline observed \>=12 weeks from start date and the new lesions verified on the next bone scan \>=6 weeks later (a total of \>=2 new lesions compared to baseline).
| Months | Dose Escalation Cohort (Phase 1) | Cohort 2: Treatment-naive Metastatic CRPC (Phase 2) | Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2) |
|---|---|---|---|
| Phase 1 and 2: Progression-free Survival (PFS) | 16.82 (11.76 to NA) | 36.37 (16.66 to NA) | NA (NA to NA) |
Objective Response Rate was defined as the percentage of participants with best overall response (OR) of confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.0 (RECIST). Where, CR defined as disappearance of all target lesions. Any pathological lymph nodes must had reduction in short axis to less than 10 millimeter (mm). PR defined as at least 30 percent (%) decrease in sum of the diameters of the target lesions. Confirmed responses were those that persisted on repeat imaging study for at least 4 weeks after initial documentation of response.
| Percentage of Participants | Dose Escalation Cohort (Phase 1) | Cohort 1: Non-metastatic CRPC (Phase 2) | Cohort 2: Treatment-naive Metastatic CRPC (Phase 2) | Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2) |
|---|---|---|---|---|
| Phase 1 and 2: Objective Response Rate | 20 (2.52 to 55.61) | 0 (0 to 97.50) | 50 (15.70 to 84.30) | 0 (0 to 30.85) |
Collected over Up to approximately 7 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation Cohort (Phase 1) | 0/30 (0%) | 7/30 (23.3%) | 29/30 (96.7%) |
| Cohort 1: Non-metastatic CRPC (Phase 2) | 0/51 (0%) | 16/51 (31.4%) | 49/51 (96.1%) |
| Cohort 2: Treatment-naive Metastatic CRPC (Phase 2) | 2/25 (8%) | 10/25 (40%) | 25/25 (100%) |
| Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2) | 0/21 (0%) | 6/21 (28.6%) | 21/21 (100%) |
| Event | Dose Escalation Cohort (Phase 1) | Cohort 1: Non-metastatic CRPC (Phase 2) | Cohort 2: Treatment-naive Metastatic CRPC (Phase 2) | Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2) |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/30 | 0/51 | 1/25 | 2/21 |
| Back PainMusculoskeletal and connective tissue disorders | 0/30 | 0/51 | 0/25 | 2/21 |
| AnaemiaBlood and lymphatic system disorders | 0/30 | 1/51 | 0/25 | 1/21 |
| Food PoisoningGastrointestinal disorders | 0/30 | 0/51 | 0/25 | 1/21 |
| HypocalcaemiaMetabolism and nutrition disorders | 0/30 | 0/51 | 0/25 | 1/21 |
| Spinal Cord CompressionNervous system disorders | 0/30 | 0/51 | 1/25 | 1/21 |
| SyncopeNervous system disorders | 0/30 | 0/51 | 0/25 | 1/21 |
| HaematuriaRenal and urinary disorders | 0/30 | 1/51 | 0/25 | 1/21 |
| Urinary RetentionRenal and urinary disorders | 0/30 | 2/51 | 0/25 | 1/21 |
| Cardiac Failure CongestiveCardiac disorders | 0/30 | 1/51 | 1/25 | 0/21 |
| Event | Dose Escalation Cohort (Phase 1) | Cohort 1: Non-metastatic CRPC (Phase 2) | Cohort 2: Treatment-naive Metastatic CRPC (Phase 2) | Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2) |
|---|---|---|---|---|
| FatigueGeneral disorders | 16/30 | 34/51 | 15/25 | 11/21 |
| NauseaGastrointestinal disorders | 9/30 | 20/51 | 14/25 | 7/21 |
| Abdominal PainGastrointestinal disorders | 7/30 | 10/51 | 12/25 | 1/21 |
| DiarrhoeaGastrointestinal disorders | 9/30 | 22/51 | 11/25 | 8/21 |
| Back PainMusculoskeletal and connective tissue disorders | 12/30 | 14/51 | 6/25 | 4/21 |
| ConstipationGastrointestinal disorders | 10/30 | 9/51 | 3/25 | 4/21 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 10/30 | 12/51 | 7/25 | 6/21 |
| Musculoskeletal PainMusculoskeletal and connective tissue disorders | 7/30 | 5/51 | 2/25 | 6/21 |
| Musculoskeletal Chest PainMusculoskeletal and connective tissue disorders | 3/30 | 2/51 | 7/25 | 3/21 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/30 | 4/51 | 7/25 | 3/21 |
| Age, Continuous(years) | Dose Escalation Cohort (Phase 1) | Cohort 1: Non-metastatic CRPC (Phase 2) | Cohort 2: Treatment-naive Metastatic CRPC (Phase 2) | Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2) | Total |
|---|---|---|---|---|---|
| Mean | 67.7 ± 9.44 | 72.8 ± 8.73 | 70 ± 11.8 | 67.4 ± 9.28 | 70.2 ± 9.82 |
| Sex: Female, Male(Participants) | Dose Escalation Cohort (Phase 1) | Cohort 1: Non-metastatic CRPC (Phase 2) | Cohort 2: Treatment-naive Metastatic CRPC (Phase 2) | Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2) | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 30 | 51 | 25 | 21 | 127 |
| Ethnicity (NIH/OMB)(Participants) | Dose Escalation Cohort (Phase 1) | Cohort 1: Non-metastatic CRPC (Phase 2) | Cohort 2: Treatment-naive Metastatic CRPC (Phase 2) | Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 0 | 0 | 3 |
| Not Hispanic or Latino | 29 | 49 | 25 | 21 | 124 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dose Escalation Cohort (Phase 1) | Cohort 1: Non-metastatic CRPC (Phase 2) | Cohort 2: Treatment-naive Metastatic CRPC (Phase 2) | Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 3 | 0 | 2 | 5 |
| White | 30 | 47 | 25 | 19 | 121 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Dose Escalation Cohort (Phase 1) | Cohort 1: Non-metastatic CRPC (Phase 2) | Cohort 2: Treatment-naive Metastatic CRPC (Phase 2) | Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2) | Total |
|---|---|---|---|---|---|
| United States | 30 | 51 | 25 | 21 | 127 |
Ran from Jul 2010 to primary completion in Aug 2012, 24 months.
Results were first posted in Jul 2018, 5 years 11 months after primary completion. A results delay was requested in Jan 2014.
Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's 24 months is below that.
Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apalutamide
Aragon Pharmaceuticals, Inc. →